STOCKHOLM, May 19, 2021 /PRNewswire/ — Eurocine Vaccines has signed an evaluation agreement, a Material Transfer Agreement, with an innovative, North American, small public company, regarding the evaluation of Endocine™ together with a vaccine candidate against COVID-19. Studies in one or two animal species will be conducted to study both potency and safety.
Endocine™ is Eurocine Vaccines’ proprietary adjuvant platform based on natural lipid compounds and formulated as a liposomal dispersion. The manufacture of bulk adjuvant has been established in pilot-scale at GMP conditions and shown excellent safety and tolerability in more than 400 human subjects after nasal administration in five clinical trials.
The platform Endocine™ has been evaluated with several different vaccine antigens, both viral and bacterial, and found compatible with peptides, proteins, polysaccharides, VLPs, as well as split and whole pathogens.
More about Endocine™ can be found at:
https://www.eurocine-vaccines.com/the-portfolio/
If positive data are obtained using Endocine™, the technology may be applied using other vaccine candidates in the collaboration.
Contact:
Hans Arwidsson, Ph.D., MBA
CEO of Eurocine Vaccines AB
hans.arwidsson@eurocine-vaccines.com
+46 70 634 0171
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
|
Eurocine Vaccines´ Adjuvant Technology Endocineâ„¢ is evaluated with a vaccine candidate against COVID-19 |
|
|
https://news.cision.com/eurocine-vaccines/i/liposome,c2914590 |
Liposome |
View original content:http://www.prnewswire.com/news-releases/eurocine-vaccines-adjuvant-technology-endocine-is-evaluated-with-a-vaccine-candidate-against-covid-19-301295078.html
SOURCE Eurocine Vaccines
